Skip to main content

Table 1 Background of all patients and patients with exon 19 deletion

From: Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

  

All patients

(N = 57)

tissue del19a

(n = 29)

Gender

Male

26 (45.6%)

16 (55.2%)

Female

31 (54.4%)

13 (44.8%)

Age

Median (Range)

69 (37–78)

68 (37–77)

Stage

Postoperative recurrence

16 (28.1%)

13 (44.8%)

III

2 (3.5%)

1 (3.4%)

IV

39 (68.4%)

15 (51.7%)

Smoking history

Yes

21 (36.8%)

17 (58.6%)

No

36 (63.2%)

12 (41.4%)

Performance status

0

24 (42.1%)

8 (27.6%)

1

33 (57.9%)

21 (72.4%)

  1. adel19, exon 19 deletion